CVRx, Inc. Common Stock (CVRX) is a publicly traded Healthcare sector company. As of May 21, 2026, CVRX trades at $6.06 with a market cap of $157.62M and a P/E ratio of -3.00. CVRX moved +1.08% today. Year to date, CVRX is -20.99%; over the trailing twelve months it is -13.30%. Its 52-week range spans $4.30 to $18.55. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces CVRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Humana Covers Barostim for 5.2M Medicare Advantage Members Starting May 2026: CVRx secured Medicare Advantage coverage from Humana for its Barostim heart failure therapy, covering approximately 5.2 million members across 46 states effective May 1, 2026. The policy applies to FDA-approved indications and BENEFIT-HF trial participants and follows January reimbursement wins including Category I CPT codes and CMS IDE coverage.
| Metric | Value |
|---|---|
| Price | $6.06 |
| Market Cap | $157.62M |
| P/E Ratio | -3.00 |
| EPS | $-2.01 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.55 |
| 52-Week Low | $4.30 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $59.07M |
| Net Income | $-52.66M |
| Gross Margin | 86.18% |
6 analysts cover CVRX: 0 strong buy, 5 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.